Sana Biotechnology, Inc. surged after hedge fund manager Eric Jackson called it a potential "100-bagger" due to its pioneering diabetes cell therapy. Sana Biotechnology's breakthrough islet cell ...
Hertel is now home to a superb Yemeni coffee and tea café called Sana’a. This local offering of the Sana’a concept is owned and operated by Yaseen Abraq, however the origins of the Yemeni café are ...
General view of the aftermath of the Israeli air strike that targeted the Haziz power station in southern Sanaa. The Israeli Air Force attacked Yemen's Sana'a airport on Wednesday, destroying the last ...
SANA develops engineered cell therapies for diabetes, autoimmune diseases, and cancer using ex vivo HIP and in vivo fusogen platforms. SC291 is their CD19‑targeted allogeneic CAR-T candidate which ...
Sana Biotechnology SANA, a clinical-stage company, is expected to report its fourth-quarter results soon. The company leverages its proprietary hypoimmune technology to develop cell engineering ...
Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the top strong buy stocks under $5 to buy now. In a report released on August 21, Reni Benjamin from Citizens JMP reiterated a Buy rating on Sana ...
Sana Biotechnology SANA, a gene-editing company, creates and delivers engineered cells as medicines for patients. The company recently secured three investigational new drug (IND) application ...
Sana Biotechnology soared by 14.53 percent on Wednesday to finish at $4.02 apiece as investors loaded portfolios ahead of its business updates next week.
Sana Biotechnology CEO Steve Harr cuts the ribbon at the company’s new manufacturing facility in Bothell, Wash., on Friday. Washington state Rep. Suzan DelBene, Bothell Mayor Mason Thompson, and Sana ...
Sana Biotechnology Inc. (NASDAQ:SANA) is a must-buy penny stock according to analysts. On November 7, Bank of America Securities analyst Alec Stranahan reaffirmed a Buy rating on Sana Biotechnology ...
The first human-tested weight-loss drug that burns calories through creatine-based heat generation, without reducing appetite, has successfully completed its Phase I trial. Scientists from the ...